Details of the Drug Combination

General Information of Drug Combination (ID: DCR518D)

Drug Combination Name
Mometasone Montelukast
Indication
Disease Entry Status REF
Asthma Phase 1 [1]
Component Drugs Mometasone   DM45OJN Montelukast   DMD157S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Mometasone
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Approved [2]
Allergic rhinitis CA08.0 Approved [2]
Exanthem N.A. Approved [2]
Granuloma annulare N.A. Approved [2]
Intrinsic asthma N.A. Approved [2]
Primary cutaneous T-cell lymphoma N.A. Approved [2]
Skin allergy 4A82 Approved [3]
Asthma CA23 Investigative [2]
Sinusitis CA0A.Z Investigative [2]
Mometasone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Agonist [7]
------------------------------------------------------------------------------------
Mometasone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Indication(s) of Montelukast
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Approved [4]
Allergic rhinitis CA08.0 Approved [4]
Asthma CA23 Approved [5]
Intrinsic asthma N.A. Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [6]
Montelukast Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUMAN cysteinyl leukotriene receptor (CysLTR) TTSB6CA CLTR1_HUMAN; CLTR2_HUMAN Antagonist [9]
Leukotriene CysLT1 receptor (CYSLTR1) TTGKOY9 CLTR1_HUMAN Antagonist [10]
------------------------------------------------------------------------------------
Montelukast Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [11]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [12]
------------------------------------------------------------------------------------
Montelukast Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [13]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [13]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [14]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [15]
------------------------------------------------------------------------------------

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029434)
2 Mometasone FDA Label
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 Montelukast FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3340).
6 The COvid-19 Symptom MOntelukast Trial (COSMO)
7 Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92.
8 Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
9 As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020 May 11;142:109828.
10 Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
11 Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60.
12 Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93.
13 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14 Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37.
15 In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.